Start by having a genetic counselor involved before and after the test, and bring the younger adult's own treating clinician into that conversation, not just family members. Once a familial Alzheimer's mutation has been confirmed in one relative, the joint ACMG/NSGC practice guideline requires formal genetic counseling before any additional family member is tested, precisely because the results are hard to interpret alone and harder to discuss without guidance. This matters most for people in their 30s, 40s, or 50s with memory complaints, because early-onset Alzheimer's is the form these familial genes cause. Getting the conversation right — who orders the test, who explains the result, and who else needs to be told — shapes how the person and their family cope with what comes next.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who Should Actually Be Tested, and Why That Decision Comes First
- What the Panel Can and Cannot Tell You
- How the Posttest Conversation Should Be Structured
- What a Positive Result Means for Insurance
- When a Result Comes From a Research Study Instead of a Clinic
- Frequently Asked Questions
Who Should Actually Be Tested, and Why That Decision Comes First
Diagnostic genetic testing is appropriate for a symptomatic younger adult when at least one of several conditions applies: a family history of dementia, an unknown family history such as an adoption, a pattern of inheritance suggesting one parent passes the condition to roughly half of their children (autosomal-dominant) with at least one early-onset case, or a relative already confirmed to carry a mutation in the PSEN1, PSEN2, or APP genes, according to the ACMG/NSGC guideline. This is a different situation from testing someone who has no symptoms but wants to know their risk because a relative tested positive — that is predictive testing, and it carries its own counseling requirement.
Before ordering anything, the guideline directs counselors to watch for a specific problem: a relative, rather than the affected person, pushing for the test. If the symptomatic individual shows any aversion to testing, the guideline states that testing should not proceed — DNA banking, which preserves a sample for future use without running the analysis now, is the offered alternative. That protects the person with memory problems from being tested against their own wishes because someone else in the family wants an answer.
What the Panel Can and Cannot Tell You
The familial Alzheimer's panel only looks for mutations that cause early-onset disease. It does not test for the more common late-onset form of Alzheimer's, and a negative result on this panel says nothing about that separate, much larger category of risk, per ARUP Laboratories' test documentation. That distinction needs to be stated plainly when discussing results, because a "negative" result is often misread as "no risk." Even within early-onset disease, the panel has real limits. A causative variant turns up in only about 60 to 80 percent of people with early-onset Alzheimer's who are tested, according to ARUP.
An inconclusive result is common, not a sign the test was done wrong — it means the current panel does not capture every genetic cause of early-onset disease. When a mutation is found, which gene it's in changes the conversation substantially. A Blue Cross NC medical policy summarizing the clinical literature reports that PSEN1 mutations are fully penetrant — meaning everyone who carries one eventually develops the disease — with symptom onset averaging more than 10 years earlier than PSEN2. PSEN2 carries about 95 percent penetrance, so some carriers may not develop symptoms. PSEN1 accounts for roughly 98 percent of detected early-onset familial cases, APP for 10 to 15 percent, and PSEN2 for under 5 percent, so the gene identified tells a family roughly what trajectory to expect.
- PSEN1: full penetrance, earliest average onset
- APP: second most common, moderate representation among detected cases
- PSEN2: about 95 percent penetrance, latest average onset, least common
How the Posttest Conversation Should Be Structured
Posttest counseling should happen in person with the ordering provider or a genetic counselor, not delivered as a phone call or a lab report left to speak for itself, according to ARUP's consent documentation. That conversation covers the result itself and also revisits, deliberately, who the person plans to tell — a parent, siblings, adult children — because that decision affects relatives who may now face their own choice about testing. This two-part structure matters because a result is not just personal information.
Once one family member's mutation is identified, it opens the door to predictive testing for every at-risk relative, and the ACMG/NSGC guideline requires each of those relatives to go through their own counseling before testing, separate from the original diagnosis. Discussing the result with the person tested should include planning for how and when that information reaches the people it also concerns. Unresolved ethical debate remains over the harms of early disclosure — anxiety, stigma, and misunderstanding about what a result actually means — and that debate is sharper for probabilistic risk markers like APOE than for a deterministic familial mutation, according to 2025 reporting from Thomas Jefferson University. A familial PSEN1, PSEN2, or APP result is close to deterministic, so the counseling conversation should be clear about that difference rather than hedging it as a probability.
What a Positive Result Means for Insurance
A positive result has consequences outside the clinic that belong in the same conversation. The federal Genetic Information Nondiscrimination Act, known as GINA, stops health insurers from using a positive familial Alzheimer's result to raise premiums or deny health coverage.
GINA does not extend to life, disability, or long-term-care insurance, and reporting on this gap confirms insurers in those three markets can legally factor a genetic result into underwriting decisions. This has a practical consequence worth raising before testing, not after: people who learn they carry a related risk variant go on to buy long-term-care insurance at roughly five times the average rate, and an LTC insurer can legally require a genetic test before issuing a policy, according to Harvard-linked research reported by Genomes2People. Anyone considering disability or long-term-care coverage should look into securing it before testing, since a confirmed mutation can affect what's available afterward.
- Health insurance: protected under GINA regardless of result
- Life insurance: GINA does not apply; insurers can use the result
- Disability insurance: GINA does not apply; insurers can use the result
- Long-term-care insurance: GINA does not apply; insurers can require testing
When a Result Comes From a Research Study Instead of a Clinic
Some younger adults with memory problems first encounter this testing through a research study rather than a doctor's order. In research settings such as the LEADS study, participants are asked separately whether they want to receive results for any pathogenic mutation identified, and a negative finding there is not confirmed in a CLIA-certified lab — the accreditation standard for clinical-grade testing, according to the LEADS study protocol.
A negative research result cannot be treated as equivalent to a clinical lab result for medical decision-making. Anyone who received a result through a research protocol should raise that distinction directly in conversation with their clinician: a research finding, positive or negative, may need to be confirmed through separately ordered clinical testing before it informs decisions about insurance, family disclosure, or treatment planning.
Frequently Asked Questions
Does a negative result on the familial panel mean no Alzheimer's risk at all?
No. The panel only screens for early-onset, familial mutations in PSEN1, PSEN2, and APP; it says nothing about the more common late-onset form of the disease, per ARUP Laboratories.
Can a family member request testing on behalf of someone with memory problems who doesn't want it?
No. The ACMG/NSGC guideline directs against testing a symptomatic person who shows aversion to it, and names DNA banking as the alternative when a relative is pushing for an answer the patient doesn't want. Source.
Should insurance be arranged before or after genetic testing?
Before, if possible. Life, disability, and long-term-care insurers are not covered by GINA's protections and can legally use a confirmed result in underwriting decisions. Source.
